Analyst Serge Belanger of Needham maintained a Buy rating on KalVista Pharmaceuticals, retaining the price target of $28.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Serge Belanger has given his Buy rating due to a combination of factors that highlight KalVista Pharmaceuticals’ strong market position and future potential. The company’s lead product, Ekterly, has shown significant promise, achieving a notable market share shortly after its approval. This rapid uptake indicates a strong demand for oral therapies in the hereditary angioedema (HAE) market, where Ekterly is positioned as a pioneer.
Furthermore, the recent results from Pharvaris’ trial do not diminish Ekterly’s standing, as the differences in trial design make direct comparisons challenging. With Ekterly setting a high efficacy benchmark, KalVista is well-positioned to maintain its competitive edge. The expectation that the market will increasingly shift towards oral therapies further supports the positive outlook for KalVista, justifying the Buy rating.
According to TipRanks, Belanger is a 5-star analyst with an average return of 10.1% and a 48.40% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Cormedix, Viridian Therapeutics, and KalVista Pharmaceuticals.